A practical reference on melanocortin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-01 and is reviewed periodically as new material appears.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Clinical identification of P. aeruginosa may include identifying the production of both pyocyanin and fluorescein, as well as its ability to grow at 42 °C. P. aeruginosa is capable of growth in diesel and jet fuels, where it is known as a hydrocarbon-using microorganism, causing microbial corrosion. It creates dark, gellish mats sometimes improperly called "algae" because of their appearance.
=== Using the Poisson–Boltzmann equation === Some methods are based on solutions to the Poisson–Boltzmann equation (PBE), often referred to as FDPB-based methods (FDPB stands for "finite difference Poisson–Boltzmann"). The PBE is a modification of Poisson's equation that incorporates a description of the effect of solvent ions on the electrostatic field around a molecule. The H++ web server, the pKD webserver, MCCE2, Karlsberg+, PETIT and GMCT use the FDPB method to compute pKa values of amino acid side chains. FDPB-based methods calculate the change in the pKa value of an amino acid side chain when that side chain is moved from a hypothetical fully solvated state to its position in the protein. To perform such a calculation, one needs theoretical methods that can calculate the effect of the protein interior on a pKa value, and knowledge of the pKa values of amino acid side chains in their fully solvated states.
In 2013, he introduced legislation that would halve the state's corporate income tax and reduce taxes on C corporations. Schmitt and supporters promoted the tax as a way to match the Kansas experiment, while opponents called the taxes economically unsustainable. The legislation, enacted in 2014, also lowered state income taxes by 0.1% beginning in 2018. In 2016, Schmitt joined 23 other Republican members of the State Senate in voting in favor of SB 656, a bill that removed the requirement for a permit to open carry and added a "stand your ground" provision. After it passed the state legislature, Governor Jay Nixon vetoed the bill, but the veto was overridden by the legislature.
== Life cycle == Like many species of bamboo, black bamboo synchronizes its flowering, with flowering events happening every 40-120 years. According to one source, it has bloomed every 120 years "since records have been kept". It is monocarpic, that is, after flowering, the plants die. Henon bamboo flowers every 120 years and is predicted to flower in the 2020s. Since it is widely distributed in Japan, dieback of its stands may cause serious social and environmental problems. Moreover, Henon bamboo rarely sets fertile seeds, so it is not clear how this species has survived over long periods in Japan.
Sources: en.wikipedia.org
The song's success benefited from appearing in the John Hughes films Sixteen Candles (1984) and Weird Science (1985) from the time period, and it would later appear in Amy Heckerling's Clueless (1995) and in the horror film Devil's Due (2014). Meanwhile, another General Public song, "Taking the Day Off" was featured in Ferris Bueller's Day Off (1986). For the follow-up album, White and Stoker were replaced by brothers Gianni and Mario Minardi on guitar and drums, respectively. Hand to Mouth was significantly less successful than their debut album, and the band dissolved soon after its release. The 1993 reissue of the album includes "Taking the Day Off" and other non-album songs and remixes. Roger and Wakeling worked on various solo projects for the next few years, before reconstituting General Public in 1994 to perform a cover version of the Staple Singers' hit "I'll Take You There" for the Threesome film soundtrack. The new General Public line-up retained only vocalists Wakeling and Roger from previous incarnations; the vocal duo was now backed by Michael Railton (keyboards), Randy Jacobs (guitars), Wayne Lothian (bass), Thomas White (drums), and Norman Jones (percussion). "I'll Take You There" was a Top 40 hit in the US and Canada and a minor hit in the UK (No. 73). Jacobs and White then left the group, and new drummer Dan Chase was brought in. The sextet released the album Rub It Better for Epic Records in 1995, recorded in the US with the aid of Jerry Harrison, the former keyboardist and guitarist for Talking Heads producing.
S-Glutathionylation is the posttranslational modification of protein cysteine residues by the addition of glutathione, the most abundant and important low-molecular-mass thiol within most cell types. Protein S-glutathionylation is involved in the following:
=== Tolerance === Mescaline is associated with rapid tolerance development, including cross-tolerance with other psychedelics like LSD and psilocybin. This tolerance is apparent within a few days and resets after 3 or 4 days of abstinence.
=== Using a metal salt and cyclopentadienyl reagents === Sodium cyclopentadienide (NaCp) is the preferred reagent for these types of reactions. It is most easily obtained by the reaction of molten sodium and dicyclopentadiene. Traditionally, the starting point is the cracking of dicyclopentadiene, the dimer of cyclopentadiene. Cyclopentadiene is deprotonated by strong bases or alkali metals.
== History == Lamivudine/zidovudine (brand name Combivir) was introduced to the market with FDA approval in 1997. Its impact in history is significant as it was the first combination therapy with a fixed dose for HIV-positive people, and soon solidified its title as a gold standard as it was the most prescribed NRTI in initial HIV treatment for newly diagnosed patients. The arrival of Combivir was seen as a new revolution in HIV therapy, with its improved toxicity profile and tolerability, especially compared to the undesirable side effects of lone AZT therapy or the unfavorable facial and lipoatrophy seen in Stavudine monotherapy at that time.
Sources: en.wikipedia.org
11 August – A bioengineered cornea made from pig's skin is shown to restore vision to blind people. It can be mass-produced and stored for up to two years, unlike donated human corneas that are scarce and must be used within two weeks. 12 August — The National Centers for Environmental Information publish a report, where they state an all-time record cold temperature occurred in Australia during the month. On October 7, 2022, Zack Labe, a climate scientist for the NOAA GFDL releases a statement and a climate report from Berkeley Earth denying the all-time record cold temperature occurred saying, "There are still no areas of record cold so far in 2022." Labe's statement also denies the record cold temperatures in Brazil, reported by the National Institute of Meteorology in May 2022, a month before the official start of winter, was also not record cold temperatures. 13 August – Rocket Lab describes its self-funded plans in detail, first announced in early 2020, to send a probe to Venus, likely in 2023, to search for life in the planet's cloud layer, where other scientists reported the potential detection of biosignature-levels of phosphine in late 2020 and thereafter. ~14 August – As record-breaking heatwaves and droughts affect water supplies, rivers (along with shipping and nuclear reactor cooling), ecosystems, various global supply chains, health, and agriculture worldwide, in Europe, Spain domestically restricts e.g.
=== Other uses in arts, entertainment and media === C4 (New Zealand TV channel), a former New Zealand television music channel 1. c4, also called the English Opening, a chess opening Channel 4, British TV channel abbreviated "C4"
==== X-ray intensifier foils ==== In the same year as the discovery of X-rays, Mihajlo Idvorski Pupin (1858-1935) invented the method of placing a sheet of paper coated with fluorescent substances on the photographic plate, drastically reducing the exposure time and thus the radiation exposure. 95% of the film was blackened by the intensifying film and only the remaining 5% was directly blackened by the X-rays. Thomas Alva Edison identified the blue-emitting calcium tungstate (CaWO4) as a suitable phosphor, which quickly became the standard for X-ray intensifying film. In the 1970s, calcium tungstate was replaced by even better and finer intensifying films with rare earth-based phosphors (terbium-activated lanthanum oxybromide, gadolinium oxysulfide). The use of intensifying films in dental film production did not become widespread because of the loss of image quality. The combination with high-sensitivity films further reduced radiation exposure.
=== Hemolytic disease of the fetus and newborn === Incompatibility of fetal and maternal RhD antigens is the main cause of Hemolytic disease of the newborn. Approximately 15 percent of Caucasian women, 3 to 5 percent of black Africa women and less than 3 percent of Asian women are RhD negative. Accurate prenatal diagnosis is important because the disease can be fatal to the newborn and because treatment including intramuscular immunoglobulin (Anti-D) or intravenous immunoglobulin can be administered to mothers at risk. PCR to detect RHD (gene) gene exons 5 and 7 from cffDNA obtained from maternal plasma between 9 and 13 weeks gestation gives a high degree of specificity, sensitivity and diagnostic accuracy (>90 percent) when compared to RhD determination from newborn cord blood serum. Similar results were obtained targeting exons 7 and 10. Droplet digital PCR in fetal RhD determination was comparable to a routine real-time PCR technique. Routine determination of fetal RhD status from cffDNA in maternal serum allows early management of at risk pregnancies while decreasing unnecessary use of Anti-D by over 25 percent.
Sources: en.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.